"Medical headline jun" primary school students academic fraud next year or a new round of adjustment of the list of basic drugs.

(2020/07/15) Forecast 2026 global pharmaceutical companies sales ranked TOP15 (top); 1356 hospitals must return in 30 days; slow-control release tablets 23 billion market slow-disease drugs shine! 5 varieties of sought-after people to hang up ... (Click on the title, get the original text) (Pharmaceutical Time 1) Forecast 2026 Global Pharmaceutical Sales Ranking TOP15 (above) According to EvaluatePharma's consistent forecast, driven by new products of oncology, multiple sclerosis and haemophilia, Roche will lead other large pharmaceutical companies in the 2026 sales list.
Pfizer, Johnson and Johnson, Novartis, AbbVie and Mercado will follow, with more than $50 billion in revenue from drug sales in 2026.
headlines: Global pharmaceutical giants are busy launching new drugs.
"Eight Health News" Primary School Students Study Cancer Award-winning fake from dolls? Yunnan Science and Technology Association: An investigation has been launched into Yunnan primary school students Chen students who have won awards for studying genes and cancer, and have attracted widespread attention for their difficulty far beyond age and the suspicion of fraud.
yesterday afternoon, Yunnan Provincial Science and Technology Association staff responded: the leadership level attaches great importance to today the investigation team set up and launched an investigation.
headlines: The power of contract work comes from bonus points for the secondary and college entrance examinations.
the latest news out of the next year or a new round of adjustment of the base drug catalog recently the relevant departments held a meeting on the relevant issues of the base drug, and clearly plans to update and revise the current 2015 version of the basic drug catalog management methods.
in fact, as early as May, the relevant departments in 2020 work points will clearly start the adjustment of the base drug catalog in due course.
headlines: Policy multiple times to strengthen the provision and use of base drugs.
the 30 days of 1356 hospitals must be refunded July 14, the State Administration of Health Insurance issued the "General Office of the State Council on the promotion of the reform of the medical security fund supervision system" policy interpretation shows that we should speed up the promotion of medical insurance standardization and information construction, to achieve the settlement data all online.
also called for the overall promotion of the reform of the relevant medical security system and the deepening of the reform of the payment method of medical insurance.
headlines: How do dealer rebates be guaranteed? "Minnet net" slow control release tablets 23 billion market slow disease medicine bright! 5 varieties of sought-after people Fu opened on July 13, the official website of the State Drug Administration shows that Qilu Pharmaceutical's single nitric acid isosaserse slow release tablets through consistency evaluation.
-meter net data show that in 2019 China's public medical institutions terminal slow-control release film sales exceeded 20 billion yuan, 12 slow release tablets have been evaluated by enterprises, 2 are included in / proposed to be included in the national harvest;
headlines: These varieties are curved overtaking.
now and in the future: 4 varieties of panoramic description of "God drug -TRK inhibitors" at present, the market requirements for drugs, is no longer satisfied with a single drug single target single disease, broad spectrum, effective, safe, better compliance of the drug, for clinical urgent need.
PD-1 inhibitors are undoubtedly milestones in the discovery of macromolecule biopharmaceuticals in the field of tumors in recent years, while small moleculebroad-spectrum anti-tumor drugs are more concerned with TRK inhibitors.
headlines: Foreign development is in full swing.
"E drug manager" Baiji Shenzhou how to re-create the largest equity financing case of Biotech? For biopharmaceutical technology companies, financing is as important today as new drug development.
, the 10th anniversary of its founding, announced on July 13th that it had completed a $2.08 billion equity financing, breaking Moderna's record for the largest equity financing in the global biotech sector and revealing the latest progress of more assets in the pipeline.
headlines: What does $2 billion mean for Baiji Shenzhou?